metabotropic receptor

(redirected from Metabotropic)
Also found in: Medical.

metabotropic receptor

(mɪˌtæbəˈtrɒpɪk)
n
(Physiology) physiol an indirect receptor which initiates an intracellular biochemical cascade after it is triggered by an agonistic ligand. Compare ionotropic receptor
Mentioned in ?
References in periodicals archive ?
Previously, the same group of researchers found that people with PTSD had higher levels of a brain receptor called metabotropic glutamatergic receptor, or mGluR5, on the surface of brain cells, compared with healthy people who didn't have PTSD.
Glutamate modulates ionotropic N-methyl-D-aspartate (NMDA) and [alpha]-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, and a family of nonionic metabotropic receptors, or mGluRs.
This extrasynaptic glutamate can then activate presynaptic type II metabotropic glutamate receptors (mGluR2/3), which causes feedback inhibition of the release of glutamate.
It is possible that its effects are the result of increased GABA-ergic activity, decreased metabotropic glutamatergic activity, and modulation of the opioidergic system just like melatonin does.
Recent evidence also suggests a role for the metabotropic glutamate receptor 5 (mGluR5) in the pathophysiology of PTSD and AUD.
NIH-funded scientists working with mice having the same genetic mutation found in Fragile X syndrome learned that the mice have increased activity in the metabotropic glutamate receptor (mGluR), which sits atop brain cells.
Metabotropic glutamate receptors (mGluRs) are receptors located in the neurons receiving glutamic signals from IHC and coupled to effector systems through GTP-binding proteins, which can modulate or fine-tune the activity at the synapse [9].
This initial investment will support the development of novel positive allosteric modulators (PAMs) of the metabotropic glutamate receptor subtype 4 as an innovative new treatment for Parkinson's disease.
Side effects like activation of type II metabotropic glutamate receptors has been observed in many studies and main cause can be considered the neurotoxic effects of homocysteine15.
The antipsychotic-like effects of positive allosteric modulators of metabotropic glutamate mGlu4 receptors in rodents.
Yeh et al., "Blockade of metabotropic glutamate receptors inhibits cognition and neurodegeneration in an MPTP-induced Parkinson's disease rat model," Pharmacology, Biochemistry, and Behavior, vol.
Accordingly, increased synaptic activity induces an increase in blood flow through signaling mechanisms that couple glutamate release to activation of group I metabotropic glutamate receptors (mGluRI) and increased intracellular [Ca.sup.+] concentration in astrocytes.